AVROBIO, Inc. - Common Stock (OQ:AVRO)

Business Focus: N/A

Mar 02, 2024 10:41 am ET

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, KAMN, AVRO

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Catalent, Inc. (NYSE: CTLT)’s sale to...

Mar 01, 2024 05:14 pm ET

INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – SCTL, MDC, BATL, AVRO

Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...

Feb 28, 2024 12:00 am ET

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AXNX, KAMN, JNPR, AVRO

Feb 26, 2024 09:20 pm ET

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CALB, AVRO, GLT, FREE

NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Feb 26, 2024 06:50 pm ET

INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BATL, AVRO, AXNX, JNPR

NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:

Feb 26, 2024 03:41 pm ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE)

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...

Feb 24, 2024 10:23 am ET

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AVRO, CTLT, DOOR, FANG

Feb 23, 2024 05:06 pm ET

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – AXNX, JNPR, BATL, AVRO

Feb 17, 2024 12:22 pm ET

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates PGTI, AXNX, AVRO, CTLT

Feb 16, 2024 12:26 pm ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), AVROBIO, Inc. (Nasdaq – AV

Feb 15, 2024 10:00 am ET

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMGI, KRTX, SIX, AVRO

NEW YORK, Feb. 15, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Feb 14, 2024 11:11 am ET

AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AVROBIO, Inc. (NasdaqGS: AVRO) and Tectonic Therapeutic, Inc. pursuant to which pre-merger AVROBIO shareholders are expected to own approximately 22.3% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

Feb 10, 2024 10:35 am ET

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AVRO, HAYN, CTLT, EVBG

Feb 06, 2024 10:30 am ET

INVESTIGATION ALERT: Halper Sadeh LLC Investigates AVRO, CSTR, BBAI, PGTI

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Feb 06, 2024 09:50 am ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ZeroFox Holdings, Inc. (Nasdaq – ZFOX), AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro

Feb 05, 2024 07:30 pm ET

SHAREHOLDER ALERT: The M&A Class Action Launches Investigation of the Merger - AVRO, CALB, MGRC, VINE

NEW YORK, Feb. 5, 2024 /PRNewswire/ -- Juan Monteverde, founder and managing partner of Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:

Feb 03, 2024 09:36 am ET

INVESTIGATION ALERT: Halper Sadeh LLC Investigates X, SNCE, AVRO, CALB

Feb 01, 2024 01:25 pm ET

Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm

NEW YORK, Feb. 1, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.

Jan 31, 2024 02:08 pm ET

Shareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with Tectonic

MILWAUKEE, Jan. 31, 2024 /PRNewswire/ -- Ademi LLP is investigating AVROBIO, Inc. (Nasdaq: AVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Tectonic.

Jan 31, 2024 10:40 am ET

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TAST, AVRO, CALB

Jan 30, 2024 01:38 pm ET

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Jan 30, 2024 11:13 am ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna

Jan 30, 2024 09:04 am ET

AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AVROBIO, Inc. (NASDAQ: AVRO) and Tectonic Therapeutic, Inc. is fair to AVROBIO shareholders. Upon completion of the proposed transaction, pre-merger AVROBIO shareholders are expected to own approximately 22.3% of the combined company.

Jan 30, 2024 08:00 am ET

AVROBIO and Tectonic Therapeutic Announce Merger

AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”). Under the terms of the agreement, AVROBIO will acquire 100% of the outstanding equity interests of Tectonic. Upon completion of the Merger, the combined company is expected to operate under th

Sep 25, 2023 09:31 am ET

Thinking about buying stock in SoundHound AI, Lucid Group, Limbach Holdings, Avrobio, or Consolidated Water?

NEW YORK, Sept. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOUN, LCID, LMB, AVRO, and CWCO.

Jul 12, 2023 07:00 am ET

AVROBIO to Explore Strategic Alternatives

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. AVROBIO has made the determination to halt further development of its programs and to con

Jun 12, 2023 07:00 am ET

AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the closing of the previously announced agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for cystinosis to Novartis for $87.5 million in cash.

Jun 07, 2023 10:45 am ET

Thinking about buying stock in Vera Bradley, Yext, Chindata, Cerus, or Avrobio?

NEW YORK, June 7, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VRA, YEXT, CD, CERS, and AVRO.

May 24, 2023 11:30 am ET

Thinking about buying stock in Vita Coco, Phathom Pharmaceuticals, Avrobio, Nano-X Imaging, or Nextdoor?

NEW YORK, May 24, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for COCO, PHAT, AVRO, NNOX, and KIND.

May 22, 2023 07:00 am ET

AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash. AVROBIO retains full rights to its portfo

May 18, 2023 07:00 am ET

AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a collaborator-sponsored Phase 1/2 clinical trial1 evaluating an investigational gene therapy

May 11, 2023 07:00 am ET

AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2023, and provided a business update.

May 01, 2023 07:30 am ET

AVROBIO Announces Leadership Transition

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the appointment of Erik Ostrowski as interim Chief Executive Officer effective as of today. Mr. Ostrowski, who will continue as AVROBIO’s Chief Financial Officer, succeeds founding President and CEO Geoff MacKay, who is leaving to join an emerging early-stage company. The Board of Directors has begun a search to identify a permanent CEO.

Mar 23, 2023 07:00 am ET

AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2022 and provided a business update.

Mar 03, 2023 07:00 am ET

AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference

The panel will be webcast live on the Investors section of avrobio.com and will remain archived for approximately 90 days.

Feb 09, 2023 07:00 am ET

AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that updated data suggesting complete biochemical correction in the first pediatric Gaucher disease type 3 (GD3) patient treated with hematopoietic stem cell (HSC) gene therapy, including improvements in

Jan 05, 2023 07:00 am ET

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500 restricted stock units (RSUs) to one new employee as an inducement award under the company’s 2019 Inducement Plan. The grant was made in accordance with Nas

Dec 07, 2022 07:30 am ET

AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced new interim pharmacokinetic, pharmacodynamic and clinical efficacy data, showing stabilization or reversal of multiple clinically relevant measures in five patients with Gaucher disease after they receiv

Nov 17, 2022 07:00 am ET

AVROBIO to Share Comprehensive Gaucher Disease Program Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will host a virtual Gaucher Disease Program Update for analysts and investors on Wednesday, Dec. 7, 2022, starting at 8 am ET.

Nov 08, 2022 07:00 am ET

AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the third quarter ended Sept. 30, 2022 and provided a business update.

Nov 07, 2022 07:00 am ET

AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced senior management will be participating in a virtual panel titled “Genomic Medicines – Evolving Regulatory Environment and Path to Approval” at the Sixth Annual Barclays Gene Editing/Therapy Summit on Mon

Nov 03, 2022 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 13,000 restricted stock units (RSUs) to two new employees as inducement awards under the company’s 2019 Inducement Plan. The grants were made in accordance with Nasdaq Li

Oct 27, 2022 07:00 am ET

AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-02, a first-in-class investigational gene therapy that genetically modifies patients’ own hematopo

Oct 25, 2022 07:00 am ET

AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the sixth and final patient has been dosed in the collaborator-sponsored, Phase 1/2 clinical trial of an investigational gene therapy for the treatment of cystinosis. Cystinosis is a life-threatening

Oct 18, 2022 07:00 am ET

AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to investigational AVR-RD-02, a

Oct 11, 2022 07:00 am ET

AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported favorable data on the combined use of two state-of-the-art assays to evaluate the genotoxicity risk of integrating vectors used in hematopoietic stem cell (HSC) gene therapy prior to clinical use,

Oct 06, 2022 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 28,000 restricted stock units (RSUs) to two new employees as inducement awards under the company’s 2019 Inducement Plan. The grants were made in accordance with Nasdaq Li

Sep 27, 2022 07:00 am ET

AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will present new preclinical data on novel assays used to evaluate lentiviral vector safety at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 11

Sep 20, 2022 07:00 am ET

AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to AVR-RD-04, an investigational gene therapy for the treatment of cystinosis, a life-threatening disease th

Sep 14, 2022 07:28 am ET

AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Ther

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA), Research Ethics Committee (REC) and Health Research Authority (HRA) have approved the clinical trial application (CTA) submitted b

Sep 08, 2022 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 58,000 restricted stock units (RSUs) to three new employees as inducement awards under the company’s 2019 Inducement Plan. The grants were made in accordance with Nasdaq

Aug 31, 2022 07:00 am ET

AVROBIO to Participate in Four Upcoming Investor Conferences in September

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming investor conferences:

Aug 09, 2022 07:00 am ET

AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.

Aug 04, 2022 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 35,500 restricted stock units (RSUs) to three new employees as inducement awards under the company’s 2019 Inducement Plan. The grants were made in accordanc

Aug 01, 2022 07:00 am ET

AVROBIO to Participate in Two Upcoming Investor Conferences in August

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences:

Jul 13, 2022 07:00 am ET

AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for AVR-RD-05, its gene therapy for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter syn

Jul 06, 2022 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 37,500 restricted stock units (RSUs) to three new employees as inducement awards under the company’s 2019 Inducement Plan. The grants were made in accordanc

May 18, 2022 07:00 am ET

AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. The results, which will be presented today during the “Disease models and Clinical Applications: Musculo-skeletal Diseases” poster session at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Washington, D.C., demonstrate that a gene therapy using hematopoietic stem cells (HSC) si

May 17, 2022 07:00 am ET

AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported new interim data, including on new visual motor integration, motor coordination and visual perception measures, from a collaborator-sponsored, ongoing Phase 1/2 gene therapy clinical trial

May 16, 2022 07:00 am ET

AVROBIO to Present at the H.C. Wainwright Global Investment Conference

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced members of its senior management team will be presenting virtually at the H.C. Wainwright Global Investment Conference, May 23-25, 2022.

May 10, 2022 07:00 am ET

AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

May 06, 2022 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Induc

May 03, 2022 07:00 am ET

AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that new data from its ongoing, collaborator-sponsored1 Phase 1/2 clinical trial in cystinosis will be presented on May 16, 2022, at the 25th Annual Meeting of the Ame

Apr 06, 2022 07:00 am ET

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 22,000 shares of the company’s common stock to one employee as an inducement award under the company’s 2019 Inducement Plan.

Apr 05, 2022 07:00 am ET

AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the 21st Annual Needham Virtual Healthcare Conference at 9:30 a.m. ET on Tuesday, April 12, 2022.

Mar 17, 2022 07:00 am ET

AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2021, and provided a business update.

Mar 01, 2022 07:00 am ET

AVROBIO to Present at Two Upcoming Investor Conferences in March

Feb 09, 2022 07:00 am ET

AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported interim data from a collaborator-sponsored, ongoing Phase 1/2 clinical triali of AVR-RD-04, an investigational gene therapy for cystinosis, at the 18th Annual WORLD

Feb 04, 2022 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 167,000 shares of the company’s common stock to three new employees as inducement awards under

Feb 01, 2022 07:00 am ET

AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean O’Bryan as chief regulatory officer. Sean brings a wealth of experience in regulatory strategy and product development to AVROBIO, as well as keen insight into the f

Jan 28, 2022 07:00 am ET

AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowen’s 2nd Annual Genetic Medicines Summit at 2:00 p.m. ET on Thursday, Feb. 3, 2022.

Jan 27, 2022 07:00 am ET

AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSym

Jan 06, 2022 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 30,500 shares of the company’s common stock to three new employees as inducement awards under the company’s 2

Jan 04, 2022 07:00 am ET

AVROBIO Reprioritizes Pipeline Programs

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that it is shifting its portfolio priorities to focus on other clinical-stage programs and extending its cash runway into the first quarter of 2024. The company is deprioritizing its Fabry

Dec 07, 2021 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 14,500 shares of the company’s common stock to two new employees as inducement awards under the compa

Nov 24, 2021 07:00 am ET

AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a vision to free people from a lifetime of genetic disease, today hosted a panel of investigators managing the patient experience in the Phase 2 FAB-GT clinical trial of AVR-RD-01, an investigational one-time gene therapy for Fabry disease, at the 14th Internat

Nov 09, 2021 07:00 am ET

AVROBIO to Present at Two Upcoming Investor Conferences in November

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences:

Nov 08, 2021 07:00 am ET

AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present safety data from its clinical trials in Fabry disease and Gaucher disease type 1 at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) on Nov. 2

Nov 05, 2021 07:00 am ET

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 120,000 shares of the company’s common stock to the company’s new Chief Medical Officer, Essra Ridha, M.D., as an in

Nov 04, 2021 07:00 am ET

AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended Sept. 30, 2021, and provided a business update.

Nov 03, 2021 07:00 am ET

AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-05, its lentiviral gene therapy for the treatment of mucopolysaccharidosis type II (MPSII),

Oct 26, 2021 07:00 am ET

AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a vision to free people from a lifetime of genetic disease, today announced the appointment of Essra Ridha, M.D., MRCP, FFPM, as chief medical officer. Dr. Ridha brings wide-ranging expertise in early- and late-stage clinical development of ex vivo lentiviral gene t

Oct 20, 2021 07:00 am ET

AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit

AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will present at the Jefferies Virtual Gene Therapy/Editing Summit at 10:30 a.m. ET on Thursday, Oct. 28, 2021.

Oct 19, 2021 07:00 am ET

AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported new safety data from the first lentiviral gene therapy clinical trials for Fabry disease and Gaucher disease, as well as new high-resolution cellular data providing insights into the mechanisms of

Oct 06, 2021 07:00 am ET

AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present new safety data from AVROBIO’s clinical trials in Fabry disease and Gaucher disease type 1 at the virtual 28th Annual Congress of the European Society of Gene & Ce

Oct 05, 2021 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 201,750 shares of the company’s common stock to eight new employees as inducement awards under the co

Sep 03, 2021 04:01 pm ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 83,750 shares of the company’s common stock to four new employees as inducement awards under the comp

Sep 01, 2021 07:00 am ET

AVROBIO to Participate at Four Upcoming Investor Conferences

Aug 16, 2021 09:31 am ET

Thinking about buying stock in Enlivex Therapeutics, Immersion Corp, Avrobio, Blade Air Mobility, or GoHealth?

NEW YORK, Aug. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENLV, IMMR, AVRO, BLDE, and GOCO.

Aug 05, 2021 07:00 am ET

AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended June 30, 2021, and provided a business update.

Aug 04, 2021 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 75,500 shares of the company’s common stock to five new employees as inducement awards under the comp

Aug 02, 2021 07:00 am ET

AVROBIO to Present at Two Upcoming Investor Conferences in August

Jul 08, 2021 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 14,500 shares of the company’s common stock to two new employees as inducement awards under the compa

Jun 28, 2021 09:31 am ET

Thinking about buying stock in Iterum Therapeutics, Kymera Therapeutics, Senseonics, Avrobio, or ChemoCentryx?

NEW YORK, June 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITRM, KYMR, SENS, AVRO, and CCXI.

Jun 10, 2021 07:00 am ET

AVROBIO to Present at the JMP Securities Life Sciences Conference

AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the JMP Securities Life Sciences Conference at 10:30 a.m. ET on Thursday, June 17, 2021.

Jun 04, 2021 07:00 am ET

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to an aggregate of 8,250 shares of the company’s common stock to one new employee as an inducement award under the comp

May 13, 2021 07:00 am ET

AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended March 31, 2021 and provided a business update.

May 06, 2021 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 163,500 shares of the company’s common stock to five new employees as inducement awards, consisting o

May 05, 2021 10:24 am ET

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVROBIO, Inc. (“AVROBIO” or “the Company”) (NASDAQ:

May 04, 2021 03:40 pm ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVROBIO, Inc. (“AVROBIO” or “the Company”) (NASDAQ:

May 04, 2021 11:06 am ET

BREAKING ALERT: Rosen Law Firm Encourages AVROBIO, Inc. Investors with Losses to Inquire About Class Action Investigation – AVRO

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO) resulting from allegations that AVROBIO may have issued materially misleading business information to the investing public.

May 03, 2021 07:00 am ET

AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today provided an update on its regulatory plans for AVR-RD-01, the first investigational lentiviral gene therapy for Fabry disease. This update follows a recent U.S. regulatory development for Fabry disease ther

Apr 27, 2021 04:30 pm ET

AVROBIO to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that two oral presentations and two posters featuring data from its pipeline of lysosomal disorder gene therapy programs will be shared at the 24th virtual Annual Meeting of the America

Apr 06, 2021 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 140,000 shares of the company’s common stock to 10 new employees as inducement awards under the compa

Mar 18, 2021 07:00 am ET

AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

Mar 05, 2021 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 61,500 shares of the company’s common stock to five new employees as inducement awards under the comp

Mar 01, 2021 07:00 am ET

AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company’s investigational gene therapy for the treatment of cystinosis. AVR-RD-04 consists of the patient’s

Feb 25, 2021 07:00 am ET

AVROBIO to Present at Three Upcoming Investor Conferences in March

Feb 08, 2021 07:00 am ET

AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a 100% reduction, or complete clearance, of toxic substrate in the kidney biopsy of the first patient dosed with the plato® gene therapy platform in the ongoing Phase 2 FAB-GTi clinical trial

Feb 05, 2021 04:05 pm ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 10,250 shares of the company’s common stock to a new employee as an inducement award under the company’s 2019 Inducement Pla

Feb 01, 2021 07:00 am ET

AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium™ 2021

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will host a virtual investor event to discuss new data from AVROBIO’s clinical programs in Fabry disease, cystinosis and Gaucher disease type 1 presented at the virtual 17th ann

Jan 22, 2021 07:00 am ET

AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit

AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO, will present virtually at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit at 11:30 a.m. ET on Friday, Jan. 29, 2021.

Jan 19, 2021 07:00 am ET

AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer. Dr. Escolar brings deep expertise across rare diseases, with a focus on lysosomal and neurogenetic disorders. She has bee

Jan 08, 2021 07:00 am ET

AVROBIO to Present at the ICR Conference 2021

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present virtually at the ICR Conference 2021 at 11:30 a.m. ET on Thursday, Jan. 14, 2021.

Jan 07, 2021 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 85,250 shares of the company’s common stock to three new employees as inducement awards under the company’s 2

Dec 04, 2020 07:00 am ET

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Inducement P

Nov 24, 2020 04:19 pm ET

AVROBIO Announces Closing of Underwritten Public Offering

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock. The aggregate gross proceeds to the company from the offering, before deducting underwriting discounts and commission and estimated offering expenses, totaled $75 million. As previously announced, the company has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.

Nov 19, 2020 10:06 pm ET

AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Gross proceeds from the underwritten public offering will total approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the company. In addition, the company has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less unde

Nov 19, 2020 04:09 pm ET

AVROBIO Announces Proposed Public Offering of Common Stock

AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in an underwritten public offering.

Nov 17, 2020 07:00 am ET

AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced positive new data across its clinical programs in Gaucher disease type 1, Fabry disease and cystinosis, further reinforcing the potential of ex vivo lentiviral gene therapy for lysosomal disorders. Additionally, AVROBIO is further expanding its lysosomal disorder pipeline with a new program in Gaucher disease type 3, which joins the recently announced program in Hunter syndrome in a synergistic portfolio of six programs designed to preven

Nov 06, 2020 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 52,250 shares of the company’s common stock to four new employees as inducement awards under the comp

Nov 05, 2020 07:00 am ET

AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the third quarter ended Sept. 30, 2020 and provided a business update.

Oct 29, 2020 07:00 am ET

AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑01, an Investigational Gene Therapy for Fabry Disease

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-01, the company’s investigational gene therapy for the treatment of Fabry disease. AVR-RD-01, an ex-vivo, lentiviral

Oct 26, 2020 07:00 am ET

AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D Day

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will host a Virtual R&D Day for analysts and investors on Nov. 17, 2020, starting at 9:00 a.m. ET.

Oct 21, 2020 07:00 am ET

AVROBIO Appoints Dr. Gail Farfel to its Board of Directors

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Gail M. Farfel, Ph.D., to its Board of Directors. Dr. Farfel brings more than 25 years of pharmaceutical development and regulatory experience in rare diseases with both large a

Oct 06, 2020 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to 351,250 shares of the company’s common stock to six new employees as inducement awards under the company’s 2019 Inducement Pl

Oct 05, 2020 07:00 am ET

AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced an exclusive, worldwide license agreement and a collaborative research funding agreement with The University of Manchester for an investigational lentiviral gene therapy for mucopolysaccharidosis

Sep 28, 2020 07:00 am ET

AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-02, the company’s investigational gene therapy for the treatment of Gaucher disease. AVR-RD-02 consists of the patie

Sep 25, 2020 07:00 am ET

AVROBIO to Present at Two Upcoming Investor Conferences

Sep 04, 2020 07:00 am ET

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Indu

Sep 03, 2020 07:00 am ET

AVROBIO to Present at Three Upcoming Investor Conferences

Aug 07, 2020 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 34,500 shares of the company’s common stock to three new employees as inducement awards under the com

Aug 06, 2020 07:00 am ET

AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the second quarter ended June 30, 2020 and provided a business update.

Aug 05, 2020 07:00 am ET

AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference at 1:10 p.m. ET on Wednesday, Aug. 12, 2020.

Jul 08, 2020 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 138,200 shares of the company’s common stock to five new employees as inducement awards under the com

Jul 06, 2020 07:00 am ET

AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the first patient has been dosed in the company’s

Jun 29, 2020 07:00 am ET

AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Kim Raineri, as chief manufacturing and technology officer. He brings deep global experience in the cell and gene therapy industry, with a distinguished track record of innovati

May 14, 2020 07:00 am ET

AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new preclinical data for AVR-RD-03 for Pompe disease showcasing how its lentiviral gene therapy approach may potentially correct Pompe disease manifestations in the muscle and central nervous syste

May 13, 2020 07:00 am ET

AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new clinical data from its investigational programs for Fabry disease and cystinosis. The data will be presented today at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual

May 07, 2020 07:00 am ET

AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended March 31, 2020 and provided a business update.

May 06, 2020 04:05 pm ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 117,000 shares of the company’s common stock to four new employees as inducement awards under the company’s 2

May 06, 2020 07:00 am ET

AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

AVROBIO, Inc. (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and

May 05, 2020 07:00 am ET

AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company, along with its academic collaborators, will present four abstracts, including three oral and one poster presentation, and participate in two pre-meeting programs, at the 23rd Annu

May 04, 2020 07:00 am ET

AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s Proprietary Platform Globally

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a new development and commercialization agreement with Saladax Biomedical, Inc. (Saladax), a leading diagnostics provider focused on developing blood tests for personalized dosing, to develop and v

Apr 12, 2020 02:26 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO

NEW YORK, April 12, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of AVROBIO, Inc. ("AVROBIO" or the "Company") (NASDAQ: AVRO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Apr 12, 2020 02:26 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO

NEW YORK, April 12, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AVROBIO, Inc. ("AVROBIO" or the "Company") (NASDAQ: AVRO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Apr 03, 2020 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 111,750 shares of the company’s common stock to eight new employees as inducement awards under the company’s

Mar 30, 2020 04:30 pm ET

AVROBIO Outlines Response to COVID-19 and Current Assessment of Business Impact

AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today shared an update on its response to the COVID-19 pandemic and a current assessment of the impact on AVROBIO’s operations.

Mar 30, 2020 02:10 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO

Pomerantz LLP is investigating claims on behalf of investors of AVROBIO, Inc. (“AVROBIO” or the “Company”) (NASDAQ: AVRO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...

Mar 26, 2020 07:00 am ET

AVROBIO to Participate in Upcoming April Investor Conferences

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will participate at three upcoming virtual investor conferences:

Mar 25, 2020 07:47 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO

NEW YORK, March 25, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of AVROBIO, Inc. ("AVROBIO" or the "Company") (NASDAQ: AVRO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Mar 25, 2020 07:47 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO

NEW YORK, March 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AVROBIO, Inc. ("AVROBIO" or the "Company") (NASDAQ: AVRO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Mar 25, 2020 07:00 am ET

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 63,000 shares of the company’s common stock to one new employee as an inducement award under the comp

Mar 17, 2020 05:58 pm ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVROBIO, Inc. (“AVROBIO” or “the Company”) (NASDAQ:

Mar 17, 2020 01:57 pm ET

AVRO LOSS NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Announces Investigation of Securities Claims Against AVROBIO, Inc. – AVRO

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO), resulting from allegations that AVROBIO may have issued materially misleading business information to the investing public.

Mar 17, 2020 12:53 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO

Mar 16, 2020 07:00 am ET

AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update

Mar 09, 2020 07:00 am ET

AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s investigational gene therapy, AVR-RD-04, for the treatment of cystinosis. The gene therapy cons

Mar 05, 2020 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 259,750 shares of the company’s common stock to nine new employees as inducement awards under the company’s 2

Feb 24, 2020 07:00 am ET

AVROBIO to Present at the Cowen and Company 40th Annual Health Care Conference

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the Cowen and Company 40th Annual Health Care Conference at 4:50 p.m. ET on Monday, March 2, 2020, at the Boston Marriott Copley

Feb 18, 2020 04:01 pm ET

AVROBIO Announces Closing of Underwritten Public Offering

AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 4,350,000 shares of its common stock. The aggregate gross proceeds to the company from the offering, before deducting underwriting discounts and commission and estimated offering expenses, totaled approximately $100 million. As previously announced, the company has granted the underwriters a 30-day option to purchase up to 652,500 additional shares of its common stock at the public offering price, less underwriting discounts and com

Feb 12, 2020 10:08 pm ET

AVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common Stock

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 4,350,000 shares of its common stock at a public offering price of $23.00 per share. Gross proceeds from the underwritten public offering will total approximately $100 million, before deducting underwriting discounts and commissions and other offering expenses payable by the company. In addition, the company has granted the underwriters a 30-day option to purchase up to 652,500 additional shares of its common stock at the public offering price, less und

Feb 12, 2020 04:01 pm ET

AVROBIO Announces Proposed Public Offering of Common Stock

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering.

Feb 10, 2020 04:01 pm ET

AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and Plato TM Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new initial data from the first patient dosed in the investigational gene therapy program for cystinosis, showing improvements in early measures at three months compared to baseline. The company also

Feb 06, 2020 07:00 am ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 91,250 shares of the company’s common stock to three new employees as inducement awards under the com

Feb 04, 2020 07:00 am ET

AVROBIO Announces Clinical Data Presentation and Multiple Events at WORLDSymposium™ 2020

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company will provide clinical data updates for its investigational programs in Fabry disease and cystinosis, as well as present data from the first clinical use of its plato™ gene therapy platform, i

Jan 14, 2020 07:00 am ET

AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program

AVROBIO (NASDAQ: AVRO) (the “Company”), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it has received notice of clearance from the U.S. Food and Drug Administration (FDA) regarding an Investigational New Drug (IND) application for AVR-RD-02, its investigational gene therapy for

Jan 09, 2020 04:00 pm ET

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO (NASDAQ: AVRO) (the “Company”), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock option to a new employee as an inducement award under the Company’s 2019 Inducement Plan, in accordance with NASDAQ Listing Rule 5635(c)(4).

Dec 19, 2019 08:00 am ET

AVROBIO Announces First Patient Dosed Using plato™ Platform

AVROBIO (NASDAQ: AVRO) (the “Company”), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the first patient has been dosed using the Company’s plato™ gene therapy platform, which is intended to provide the foundation for the potential worldwide commercialization of AVROBIO’s gene th

Dec 16, 2019 08:00 am ET

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO (NASDAQ: AVRO) (the “Company”), a leading clinical stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock option to a new employee as an inducement award outside of the Company’s 2018 Stock Option and Incentive Plan, in accordance with NASDAQ Listing Ru

Nov 07, 2019 07:00 am ET

AVROBIO, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today reported financial results for the third quarter ended September 30, 2019 and provided a business update.

Oct 24, 2019 07:00 am ET

AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR‑RD‑02 for the Treatment of Gaucher Disease

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-02, for the treatment of Gaucher disease. AVR-RD-02 consists of the patient’s own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase),

Oct 22, 2019 07:00 am ET

AVROBIO Appoints Holly May as Chief Commercial Officer

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the appointment of Holly May, MBA, a rare diseases leader with deep experience in commercial strategy and operations, as Chief Commercial Officer

Oct 08, 2019 07:00 am ET

AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) today announced that the first patient has been dosed in the Company’s AVR-RD-04 investigational gene therapy program for cystinosis, a devastating lysosomal storage disease, in an ongoing

Oct 03, 2019 08:00 am ET

AVROBIO, Inc. to Present at Chardan’s 3rd Annual Genetic Medicines Conference

AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan’s 3rd Annual Genetic Medicines Conference on Monday, October 7, 2019.

Aug 29, 2019 07:00 am ET

AVROBIO, Inc. to Present at Upcoming Investor Conferences

AVROBIO, Inc. (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that members of its senior management team are scheduled to participate in five upcoming investor conferences.

Aug 16, 2019 08:30 am ET

AVROBIO Appoints Georgette Verdin as Chief Human Resources Officer

AVROBIO, Inc. (NASDAQ: AVRO) (“AVROBIO” or the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the appointment of Georgette Verdin as Chief Human Resources Officer (CHRO). Ms. Verdin will be responsible for all aspects of human

Aug 12, 2019 05:36 pm ET

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (NASDAQ: AVRO) (“AVROBIO” or the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2018 Stock Option and Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

Aug 08, 2019 07:00 am ET

AVROBIO Reports Second Quarter 2019 Financial Results and Provides Business Update

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today reported financial results for the second quarter ended June 30, 2019 and provided a business update.

Aug 06, 2019 08:00 am ET

AVROBIO, Inc. to Present at the 2019 Wedbush PacGrow Healthcare Conference

AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that the Company will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 2:30 p.m. ET at the Parker New York Hotel in New York City.

Jul 19, 2019 04:01 pm ET

AVROBIO Announces Closing of Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock, including 975,000 shares of its common stock pursuant to the underwriters’ exercise in full of their option to purchase additional shares at the publ

Jul 16, 2019 09:58 pm ET

AVROBIO Announces Pricing of Underwritten Public Offering of $120.25 Million of Common Stock

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $18.50 per share. Gross proceeds from the underwritten public offering totaled approximately $120.25 million, before deducting underwriting disc

Jul 16, 2019 04:01 pm ET

AVROBIO Announces Proposed Public Offering of Common Stock

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $100.0 million of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to $15.0 million of addi

Jul 15, 2019 07:00 am ET

AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) today announced the first kidney biopsy result and additional positive data from two ongoing clinical trials of its AVR‑RD‑01 investigational gene therapy in Fabry disease. To date, eight patients have been dosed in the trials – three patients in the Phase 2 FAB-2011 trial and five patients in the Phase 1 FACTs

May 13, 2019 07:00 am ET

AVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today reported financial results for the first quarter ended March 31, 2019 and provided a business update.

Apr 29, 2019 07:00 am ET

AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AVR-RD-01, its gene therapy candidate for the treatment of Fabry disease. The Company now expects to

Apr 26, 2019 04:00 pm ET

AVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the participation of its senior management in sessions at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). These include sessions on advances in gene therapy research, manufacturing challenges d

Apr 09, 2019 09:00 am ET

Detailed Research: Economic Perspectives on AVROBIO, TheStreet, Youngevity International, Universal Logistics, The Madison Square Garden, and Ooma — What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of AVROBIO, Inc. (NASDAQ:AVRO), TheStreet, Inc. (NASDAQ:TST), Youngevity...

Mar 25, 2019 07:00 am ET

AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2018 and provided a business update.

Mar 05, 2019 07:00 am ET

AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference

AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the Company will present at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019, at 8:40 a.m. ET at the Marriott Copley Place in Boston.

Feb 06, 2019 09:00 am ET

AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease

AVROBIO, Inc. (Nasdaq: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced clinical trial updates from the ongoing investigator-sponsored Phase 1 clinical study and the AVROBIO-sponsored Phase 2 clinical trial of AVR-RD-01. AVR-RD-01 is an investigational gene therapy

Feb 01, 2019 07:00 am ET

AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and investor presentation and webcast scheduled for Wednesday, February 6, 2019, at which time the Company...

Jan 18, 2019 07:00 am ET

AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy candidate for cystinosis, AVR-RD-04, is cleared to begin a Phase 1/2 clinical trial, following...

Jan 17, 2019 07:00 am ET

AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates related to the Company’s gene therapy program for AVR-RD-01 in Fabry disease will be presented at...

Jan 07, 2019 07:06 am ET

AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors

AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced the appointment of Philip J. Vickers, Ph.D., to its Board of Directors. Dr. Vickers brings a wealth of global pharmaceutical and biotechnology...

Dec 21, 2018 10:00 am ET

AVROBIO, Inc. Added to NASDAQ Biotechnology Index

AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). AVROBIO’s addition to the NBI will...

Dec 19, 2018 07:00 am ET

AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR RD 01 for the Treatment of Fabry Disease

AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today announced that the U.S. Food and Drug Administration (FDA) has granted...

Dec 18, 2018 07:05 am ET

AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the grant of non-qualified stock options to purchase 293,000 shares of common stock, effective on December 17, 2018. Such options were...

Dec 18, 2018 07:00 am ET

AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires

AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the appointment of four key senior management hires to expand and strengthen its leadership team as it prepares for the next stage of...

Nov 21, 2018 07:35 am ET

Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research High

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ONE Group Hospitality, Inc. (NASDAQ:STKS), Biofrontera AG Sponsored...

You are here

AVROBIO, Inc. - Common Stock (OQ:AVRO)

Business Focus: N/A